Integral Derivatives’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
$3.9M Sell
61,700
-68,400
-53% -$4.4M 0.1% 57
2017
Q4
$7.97M Buy
130,100
+29,500
+29% +$1.85M 0.16% 65
2017
Q3
$6.41M Buy
100,600
+48,100
+92% +$2.81M 0.12% 107
2017
Q2
$2.92M Sell
52,500
-6,400
-11% -$348K 0.06% 220
2017
Q1
$3.2M Sell
58,900
-5,400
-8% -$296K 0.06% 211
2016
Q4
$3.76M Sell
64,300
-25,100
-28% -$1.37M 0.07% 186
2016
Q3
$4.82M Buy
89,400
+45,600
+104% +$2.93M 0.1% 120
2016
Q2
$3.22M Buy
43,800
+33,600
+329% +$2.37M 0.08% 147
2016
Q1
$652K Sell
10,200
-5,900
-37% -$372K 0.02% 467
2015
Q4
$1.11M Sell
16,100
-16,100
-50% -$1.06M 0.03% 427
2015
Q3
$1.91M Buy
32,200
+3,300
+11% +$209K 0.05% 318
2015
Q2
$1.92M Sell
28,900
-10,800
-27% -$712K 0.05% 328
2015
Q1
$2.56M Buy
39,700
+2,200
+6% +$138K 0.05% 228
2014
Q4
$2.21M Buy
37,500
+12,200
+48% +$688K 0.04% 399
2014
Q3
$1.29M Sell
25,300
-17,400
-41% -$869K 0.02% 618
2014
Q2
$2.07M Buy
42,700
+35,500
+493% +$1.75M 0.04% 407
2014
Q1
$374K Sell
7,200
-2,800
-28% -$149K 0.01% 978
2013
Q4
$532K Buy
+10,000
New +$509K 0.01% 1022

Other funds holding BMY

Integral Derivatives's BMY Position: Q2 2017 in Review

Integral Derivatives sold out of Bristol-Myers Squibb (BMY) in Q2 2017, closing a stake of 20,436 shares — an estimated $1.11M sold.

Integral Derivatives first reported a position in BMY in Q4 2013 and held it in 7 quarters. The position peaked at $2.08M in Q2 2014. 1,594 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

  • Integral Derivatives reported no remaining Bristol-Myers Squibb position as of Q2 2017 after selling out during the quarter.
  • Integral Derivatives sold 20,436 Bristol-Myers Squibb shares in Q2 2017, an estimated $1.11M.
  • Integral Derivatives first reported a position in Bristol-Myers Squibb in Q4 2013 and held it in 7 quarters.
  • Integral Derivatives's Bristol-Myers Squibb position peaked at $2.08M in Q2 2014.
  • 1,594 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Integral Derivatives's 13F filing for Q2 2017, filed 14 Aug 2017.